Cancer diagnostics
Life often depends on how timely and accurately the diagnosis is made. In addition, accurate diagnosis of oncological diseases is important for making decisions when choosing the most effective treatment tactics in each specific case. To diagnose cancer and determine whether it has spread to other parts of the body, in addition to examination, doctors use data from laboratory and instrumental studies.
At the "Dobrobut" Clinical Oncology Center, everything necessary for complete and accurate diagnosis of oncological diseases is concentrated. We use state-of-the-art equipment from leading manufacturers of medical technology, which is not only informative and effective for diagnosis, but also safe. Moreover, advanced models of diagnostic devices help make the procedure as comfortable as possible.
All diagnostic procedures at the "Dobrobut" Clinical Oncology Center are carried out only with a referral from an oncologist.
Laboratory Diagnostics
A histological conclusion about the pathology is crucial for establishing an accurate diagnosis and selecting the most effective treatment strategy.
Based on the analysis of the obtained biological material, the pathologist helps determine the exact type of cancer. This specialist participates in multidisciplinary councils where decisions about the choice of treatment tactics are made.
Screening laboratory tests for detecting the most common types of cancer include: PAP test (for detecting cervical cancer), PSA test (for detecting prostate cancer), BRCA test (for identifying hereditary predisposition to ovarian and breast cancer), as well as a test for hidden blood in the stool (which helps detect the presence of colorectal cancer and rectal cancer). To determine the nature and type of the tumor, biopsy is used worldwide: the study of tissue samples in laboratory conditions, which are taken from the identified pathological focus.
Service prices:
- PAP-test (screening test of cervical smear)440 uah
- Liquid Cytology CellPrep PAP test770 uah
- Prostate-specific antigen (PSA), general410 uah
- Prostate-specific antigen (PSA), free + general710 uah
- GEN_MyGene BRCA1/2 (NGS, hereditary mutation screening, blood, Illumina)14000 uah
- Fecal immunochemical test (hemoglobin and transferrin)380 uah
- Histological examination after biopsy of bone tumor formation1870 uah
- Histological examination after excisional lymph node biopsy (1 localization)1870 uah
- Histological examination after extirpation of a cervical stump with appendages1870 uah
- Diagnostic IHC, 1st category of difficulty3000 uah
- Diagnostic immunohistochemistryof 2nd category of complexity5500 uah
- Diagnostic IHC, 3rd category of difficulty8400 uah
- HER-2 / neu gene amplification (in situ hybridization, DAKO HER-2 CISH pharmDx set) in mammary gland and stomach tumors12000 uah
- Amplification of HER‐2/NEU, FISH10500 uah
- IHC (НЕR2/neu)1650 uah
- IHC (ER, PR) study of the hormonal status of the endometrium1760 uah
- Oncomarker of the ovarian (CA 125)440 uah
- IHC p16, Ki-67, HSIL verification1760 uah
- IHC (p57, Ki-67) verification of cystic drift1760 uah
- IHC CD138, verification of chronic endometritis1320 uah
- IHC (CA 125) marker of ovarian neoplasm1650 uah
- Histological examination to determine BRAF V600 by PCR5800 uah
- Determination of BRAF V600 by PCR (CM material or peripheral blood)3500 uah
- Molecular genetic examination: panel for diagnostics of thyroid cancer mutations BRAF, NRAS, KRAS, NRAS, RET / PTC1, RET / PTC3, PAX8 / PPARg (punctate)3200 uah
- EGFR Mutations, PCR5800 uah
- ALK Translocation, FISH9000 uah
- ROS1 Translocation, FISH7400 uah
- Determination of DNA mismatch repair proteins (microsatellite stability/instability of the tumor)3100 uah
- Determination of t(9;22)(q34.1;q11.2) BCR-ABL1 (Philadelphia chromosome) by FISH method5100 uah
- Determination of BCR-ABL1 (p210) (Philadelphia chromosome) by PCR method3600 uah
- Determination of BCR-ABL1 (p190) (Philadelphia chromosome) by PCR method3300 uah
- Karyotyping in oncohematological diseases5800 uah
- Determination of t(12;21)(p13.2;q22.1) by FISH method4800 uah
- Determination of t(15;17)(q24;q21) by the FISH method4400 uah
- FISH definition of inv(16)(p13.1q22)/t(16;16)5400 uah
- Determination of del17p13 by FISH method4400 uah
- Determination of Del 5q by the FISH method5700 uah
- Determination of del(7q) by the FISH method4400 uah
- Determination of del(20q) by the FISH method7600 uah
- Interoperable study of the material (stage 1)1650 uah
- Interoperational study of the material (stage 2 and subsequent stages)1320 uah
- Micrographic surgery (Mohs, Slow Mohs) (for the second and subsequent stages, for each)1320 uah
- Micrographic surgery (Mohs, Slow Mohs) (for the first stage)2500 uah
- Histological examination after radical resection of the breast and mastectomy (one side) *3500 uah
- Histological examination after Lobectomy and pulmonectomy *3500 uah
- Histological examination after Lobectomy of the thyroid gland1870 uah
- Histological examination after gastrectomy, subtotal gastrectomy *4700 uah
- Histological examination after biopsy of soft tissue tumor formations1320 uah
- Histological examination after appendix removal during tumor processes1870 uah
- Histological examination after removal of the gallbladder in tumor processes1870 uah
- Histological examination after removal of odontogenic tumor, skull bone tumor1870 uah
- Histological examination after removal of bone and joint tumor, bone resection for tumor pathology2800 uah
- Histological examination after removal of tumor of the oral/ nasal cavities1870 uah
- Histological examination after the removal of uterine appendages with ovarian tumors (one side)1870 uah
- Histological examination after removing a tumor of the brain, spinal cord, membranes1870 uah
- Prostate-specific antigen (PSA) free + total (cito)1150 uah
- Prostate-specific antigen (PSA) total (cito)820 uah
- OncoRisk BRCA1/2 - Panel of hereditary mutations of BRCA1 and BRCA2 genes, NGS16400 uah
- OncoRisk BRCA Plus - Genetic panel for Breast and Ovarian Cancer (14 genes)13700 uah
- Histological examination after excisional biopsy of skin tumor with assessment of resection edges (for 1 localization)1320 uah
- Histological examination after penile formation excision biopsy1550 uah
- Histological examination after enucleation, partial prostatectomy1550 uah
- Immunocytochemical study of exudate fluids in metastatic processes5100 uah
- OncoRisk Colorectal - Genetic panel for colorectal cancer (19 genes)17300 uah
- OncoRisk Complete - Comprehensive panel for hereditary cancer (88 genes)28700 uah
- OncoRisk Lynch - Lynch syndrome diagnosis (5 genes)10200 uah
- OncoRisk Renis - Genetic panel for renal cancer (25 genes)17300 uah
- OncoRisk Prostate - Genetic panel for prostate cancer (15 genes)14700 uah
- Quantification of BCR-ABL1 p190 translocation by PCR4300 uah
- Quantitative determination of the leukemia marker BCR-ABL1 p210, PCR6900 uah
- Comprehensive cytogenetic testing (Karyotyping + FISH) oncohematology10500 uah
- Histological examination after removal of ureter/part of ureter (in case of tumor pathology)1550 uah
- Histological examination after wedge resection/ovarian biopsy (tumor pathology, on the one side)1870 uah
- Histological examination after biopsy of intestinal tumors (up to 3 localizations of biopsy included)1500 uah
- Histological examination after uterine removal without appendages (in case of tumor pathology)1870 uah
- Histological examination after removal of the appendages of the uterus (in case of tumor pathology, on one side)1870 uah
- Histological examination after ovarian removal (in case of tumor pathology, on one side)1870 uah
List of sources, literature ↓
- Аляев Ю.Г., Винаров А.З., Крапивин А.А. Диагностика опухоли лоханки и мочеточника. В кн.: Тезисы VI Всероссийской научно-практической конференции Актуальные вопросы лечения онкоурологических заболеваний 4-5 октября 2005 г. Онкоурология (приложение) 2005: прил.: 5-6.
- Книшов Г.В., Витовский Р.М., Захарова В.П. (2005) Опухоли сердца, проблемы диагностики и хирургического лечения. Киев, 256 с.
- Клинические рекомендации по диагностике и лечению больных с опухолями верхних мочевыводящих путей. Ассоциации онкологов России. Москва 2014.